Driving Drug Competition to Lower Cost
In any industry, competition often leads to lower prices—period.
In the U.S. pharmaceutical market, drug manufacturers can—and do—increase prices to what the market will bear for drugs that have no competition, and charge lower prices for drugs where there is robust competition. PBMs like Express Scripts are more effective in negotiating discounts when there is greater competition among prescription drugs. In the biosimilar landscape for example, biologics have little direct competition, largely due to patent litigation with biosimilar manufacturers. Having multiple competing products—whether another branded drug, multiple generics or a biosimilar—with equivalent patient benefits on the market allows PBMs to drive drug manufacturers to compete and provide patients and plan sponsors with access to lower cost drugs.
PBMs drive drug competition by:
PBMs use generic and biosimilar competition to accelerate lower drug costs
While PBMs have been using generic competition for decades to lower drug costs, biosimilars are relatively new in the marketplace. Biosimilars are clinically equivalent, lower-cost versions of biologics, which are complex medications made from natural and living sources.
Biosimilars vs. Generics
A recent Evernorth analysis estimates that biosimilar competition can save the U.S. $225 billion to $375 billion in pharmacy spend over the next decade.1
Capturing the biosimilar opportunity to lower costs
In 2019, biologics accounted for $211 billion of U.S. prescription drug spending, or 43% of total spend. For many years, the biosimilar market has been slow to develop, primarily due to resistance from pharmaceutical manufacturers—resulting in limited commercial availability and uncertain pricing dynamics.
Nevertheless, biosimilars are beginning to take greater overall market share, and the entrance of these alternative pharmaceutical options is driving lower average net costs.2
As more brand name biologics lose marketing exclusivity and biosimilars continue to come to market, the potential for PBMs to drive additional savings for clients and customers is significant.
This has been the case with recent inflammatory biosimilars coming to market, including biosimilars for Remicade. The entrance of these medicines has created effective competition that has driven down the price of the reference biologic by more than 57% in the four years between their initial market availability and January 2022.
The importance of interchangeability
Unlike most generics, biosimilars are not automatically designated as interchangeable upon FDA approval. If a patient is prescribed a branded drug that has a generic alternative, pharmacists can generally automatically substitute the lower-cost generic at the pharmacy counter. However, for biosimilars, the pharmacist would have to wait until the original biologic has a designated interchangeable biosimilar alternative in order to substitute the lower-cost alternative at the point of sale.
How competition and an interchangeable biosimilar are changing the insulin market
The long-acting insulin pen injector Lantus was launched in 2010 with a high list price that more than doubled over 2010-2014, with limited rebates. In 2015, competition entered the market and subsequently Lantus’ price increased only modestly year-over-year and rebates substantially increased.
Express Scripts announced in October 2021 that Semglee®, an interchangeable biosimilar with Lantus®, would be available as a preferred product on our National Preferred Formulary. Semglee® is paving the way for automatic substitutions in certain states, where pharmacies can automatically dispense the lower cost product, but only to the extent those states’ laws allow.
Express Scripts estimates that clients and customers saved as much as $20 million in 2022 as a result of our biosimilar formulary strategy.
Ensuring a robust biosimilars market
Based on an Evernorth analysis of Express Scripts Drug Trend Report and IDP Analytics data to model the savings opportunity of 17 widely used biologic medications with patents expected to expire by or before 2030, with the assumption that at least one biosimilar for each reference biologic will be available in the market one year after patent expiration or at the end of exclusivity, whichever is later.
https://www.pcmanet.org/biosimilars-versus-biologics-how-about-both